Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Orphazyme A's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Orphazyme A (ORPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2021
Competitors Tracked
1
Publicly traded peers
Peer Group Market Share
90.78 %
Share of combined sales, Q4 2021
Revenue Growth Y/Y
-
Peers: 301.90 %
Net Margin
-1,731.11 %
Peers: -477.24 %

Key Findings: Orphazyme A vs Its Competitors

  • TTM: Trailing 12-month revenue of 6M vs 1M combined for tracked competitors (86.9% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+168.8%) for its tracked peer group.
  • Profitability: Its -1,731.1% net margin compares with -477.2% for the peer group.
  • Peer revenue share: Orphazyme A accounted for 90.8% of combined revenue among its tracked peer group.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

ORPH Sales vs. its Competitors, Q4 2021

With a net margin of -1,731.11 %, Orphazyme A reported lower profitability than its competitors (-477.24 %).

Orphazyme A generated 90.78 % of the combined sales of its peer group.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ORPH/competitors
https://api.csimarket.com/api/v1/companies/ORPH/relationships
https://api.csimarket.com/api/v1/companies/ORPH/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

Orphazyme A vs. its Competitors, Q4 2021

Net margin

Orphazyme A -1,731.1 %
Competitors combined -477.2 %

Revenue run-rate vs trailing 12 months

Orphazyme A +300.0 %
Competitors combined +168.8 %

TTM net margin

Orphazyme A -1,731.1 %
Competitors combined -2,848.2 %

TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Orphazyme A reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.

Competitor Financial Benchmarking - TTM Commercial

TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Orphazyme A and its 4 competitor groupings. Available under Commercial License.

Entity TTM Revenue Latest Q ×4 Rev Run-rate vs TTM TTM Net Income TTM Net Margin
Orphazyme A $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitors combined $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
High-Confidence Competitors (1) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitor Financial Benchmarking

TTM revenue, run-rate and net margin benchmarking across Orphazyme A's competitor groups requires a Commercial License.

Orphazyme A's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Orphazyme A - - - Yes
Competitors combined (1) - 0% 0% 0%
High-Confidence Competitors (1) - - - 100%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q4 2021

90.8%market share
  • Orphazyme A90.8%
  • Competitors combined9.2%

Share of combined quarterly revenue of Orphazyme A and its 1 tracked competitors.

See Orphazyme A's full market share breakdown »

ORPH Stock Performance relative to its Competitors

ORPH Competitors (weighted) Percent change over the selected range

ORPH Stock Performance relative to High-Confidence Competitors

ORPH High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

Publicly Traded Peers of Orphazyme A

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Orphazyme A 30.38 5.76 -99.68 -
Cyclo Therapeutics Inc 20.70 0.87 -24.80 29
SUBTOTAL 51.09 6.63 -124.48 29

Sources: Orphazyme A's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Orphazyme A versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Orphazyme A's Competitors Named by the Company

Competitive relationships identified from Orphazyme A reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Ladrx Corporation Company report 85% 2022 to 2026 3
Cyclo Therapeutics Inc Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Orphazyme A's named competitors require a Commercial License.

Methodology: relationships are extracted from Orphazyme A reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Orphazyme A's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Orphazyme A 30 - -
Cyclo Therapeutics Inc 21 30,025 -855,173
PEERS TOTAL 21 30,025 -855,173

Orphazyme A's Profitability & Cost Structure

Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (452 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.
Metric Company Industry Difference
Gross Margin 0.00 % 37.76 % (avg) -37.8 pp
Operating Margin - industry median -
EBITDA Margin - -6.31 % (avg) -
Capital Intensity (Capex / Revenue) 0.25 % 7.36 % (avg) -7.1 pp

Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.

Orphazyme A's Valuation vs Competitive Position

Valuation multiples vs the Major Pharmaceutical Preparations industry average (452 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.
Metric Company Industry Average Difference
P/E - 26.9x -
EV / EBITDA - 16.9x -
P/B 86.7x 4.3x +82.4x
Return on Equity -7,013.14 % industry aggregate -7,034.77 %
Return on Invested Capital -267.69 % -9.73 % (avg) -257.96 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Orphazyme A's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.
Force Assessment Basis
Barriers to Entry Lower than typical for the industry Capital intensity (capex / revenue) of 0.25 % vs industry average 7.36 % (see Profitability & Cost Structure above)
Supplier Power Not covered on this page See Orphazyme A's dedicated suppliers page for concentration and dependency data
Buyer Power Not covered on this page See Orphazyme A's dedicated customers page for concentration and dependency data
Threat of Substitutes - No systematic data source for cross-product substitution exists in this system; not estimated

Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.

Orphazyme A's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

  • Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).

Weaknesses

  • Return on equity 7,034.8 points below the industry aggregate.
  • Piotroski F-Score of 2 or below, the standard financial-distress signal.

Opportunities

No rule matched.

Threats

No rule matched.

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Orphazyme A's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Orphazyme A 0.79 1.23 3.58 0.22
Cyclo Therapeutics Inc 0.33 0.61 - 0.11

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Orphazyme A's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Orphazyme AQ4 2021----
Cyclo Therapeutics Inc Q3 2024-52.8 %+89.9 %--
PEERS TOTAL+1,109.4 %+4,767.5 %--

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Orphazyme A's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Orphazyme AQ4 2021---96.0 %-96.0 %
Cyclo Therapeutics Inc Q3 2024-+25.5 %--

Orphazyme A's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Orphazyme A---1.29-
Cyclo Therapeutics Inc ---7.490.52

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Orphazyme A's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Orphazyme A-5.28-0.0421.38
Cyclo Therapeutics Inc -23.78---
PEERS AVERAGE-7.710.07-

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API Connect Your AI